Acetanilides

Pacira Announces FDA Approval of Enhanced EXPAREL Manufacturing Process

Retrieved on: 
Monday, August 2, 2021
Branches of biology, Membrane biology, Local anesthetics, Drugs, Pharmacology, Acetanilides, Bupivacaine, Piperidines, Liposome, Approved Drug Products with Therapeutic Equivalence Evaluations, Vesicle

PARSIPPANY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s enhanced manufacturing process for EXPAREL® (bupivacaine liposome injectable suspension) which is housed at a custom facility in Swindon, England under a partnership with Thermo Fisher Scientific Pharma Services. The company expects to start selling commercial product manufactured in this 200-liter suite later this year.

Key Points: 
  • This FDA approval underscores the quality assurance of our enhanced manufacturing process, which is essential as we scale the production of EXPAREL, said Dave Stack, chairman and chief executive officer of Pacira BioSciences.
  • The patent, Manufacturing of Bupivacaine Multivesicular Liposomes, claims composition of EXPAREL prepared by the improved manufacturing process and has an expiration date of January 22, 2041.Pacira submitted this patent for listing in the FDAs Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) in July 2021.
  • The companys long-acting local analgesic, EXPAREL (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012.
  • EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting.

Hyloris Announces Launch of Maxigesic® IV, a Novel Non-Opioid Pain Treatment, in Key European Markets

Retrieved on: 
Thursday, July 8, 2021
Drugs, Hepatotoxins, Analgesics, Health care, Phenols, Nonsteroidal anti-inflammatory drugs, Acetanilides, Paracetamol, Ibuprofen, Opioid

Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion.

Key Points: 
  • Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion.
  • Hyloris partner AFT Pharmaceuticals works together with distribution partners with strong local presence to commercialise the product globally.
  • Maxigesic IV is currently licensed in more than 100 countries across the globe, and it has been registered in 24 countries.
  • Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: We are pleased that AFT and its partner Ever Pharma have now launched Maxigesic IV in Germany and Austria.

Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021

Retrieved on: 
Tuesday, June 8, 2021
Sales, Accounts receivable, Acetanilides, Bupivacaine, Piperidines

PARSIPPANY, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL (bupivacaine liposome injectable suspension) and iovera of $41.2 million and $1.0 million, respectively, for the month of May 2021.

Key Points: 
  • PARSIPPANY, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL (bupivacaine liposome injectable suspension) and iovera of $41.2 million and $1.0 million, respectively, for the month of May 2021.
  • EXPAREL average daily sales for the month of May 2021 were 162 percent of May 2020 and 105 percent of April 2021.
  • EXPAREL sales continue to significantly outperform the elective surgery market recovery, with May marking our fourth consecutive month of sequential growth in average daily sales.
  • In order to provide greater transparency, the company will continue to report monthly intra-quarter unaudited net product sales until it has gained enough visibility around the impacts of COVID-19.

Global Paracetamol (CAS 103-90-2) Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021
Health, Pharmaceutical, Drugs, Hepatotoxins, Acetanilides, Antipyretics, Paracetamol, Pesticides, Phenols

The "Paracetamol (CAS 103-90-2) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Paracetamol (CAS 103-90-2) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The fifth chapter deals with Paracetamol market trends and forecast, distinguish Paracetamol manufacturers and suppliers.
  • The Paracetamol global market report key points:

Pacira BioSciences Announces Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block

Retrieved on: 
Wednesday, May 26, 2021
Acetanilides, Bupivacaine, Piperidines

Pacira plans to submit the full results from the Phase 3 STRIDE study for presentation at future scientific conferences and for publication in a peer-reviewed journal.

Key Points: 
  • Pacira plans to submit the full results from the Phase 3 STRIDE study for presentation at future scientific conferences and for publication in a peer-reviewed journal.
  • In the absence of preoperative multimodal therapy, the study demonstrated the advantages of EXPAREL versus bupivacaine from 24 hours and beyond.
  • The findings from this study are valuable and demonstrate the ability of an EXPAREL long-acting lower extremity nerve block to provide significant pain relief that extends to 96 hours.
  • We look forward to discussing these important findings with FDA and defining the next steps for broadening the EXPAREL label to include lower extremity nerve blocks.

Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours

Retrieved on: 
Thursday, May 13, 2021
Palliative care, Medical specialties, Acetanilides, Bupivacaine, Piperidines, Pain, Opioid, Pain management, Clinical medicine

Our existing commercial team will immediately begin working with current accounts to gain formulary access, with full commercial availability expected by July 2021.

Key Points: 
  • Our existing commercial team will immediately begin working with current accounts to gain formulary access, with full commercial availability expected by July 2021.
  • "\nZYNRELEF is the first and only therapy for postoperative pain management to be rigorously tested in Phase 3 studies and demonstrate superiority to bupivacaine solution.
  • ZYNRELEF demonstrated superior, sustained postoperative pain relief for up to 72 hours and decreased the need for opioids, with more patients opioid-free compared to bupivacaine solution.
  • "Inadequate postoperative pain management has been associated with poor patient outcomes, causing a substantial burden on public health and contributing to recovery delays.

Investigation Report on China's Iodixanol Market, 2016-2020 & 2021-2025: Relevant Concepts, Sales, Major Manufacturers, Pricing & Prospects - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Health, Pharmaceutical, Radiocontrast agents, Medical imaging, Companies, Projectional radiography, Acetanilides, Benzamides, Iodixanol, Amersham, Buckinghamshire, Angiography, GE Healthcare, General Electric

b'The "Investigation Report on China\'s Iodixanol Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nIodixanol is a third-generation contrast agent that has good solubility and is isotonic to plasma.

Key Points: 
  • b'The "Investigation Report on China\'s Iodixanol Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nIodixanol is a third-generation contrast agent that has good solubility and is isotonic to plasma.
  • It is used for cardiovascular angiography, cerebrovascular angiography, abdominal angiography, and so on.
  • Iodixanol was developed by Nycomed, a Norwegian company, naming VISIPAQUE (Nycomed was acquired by GE after the merge with Amersham, and become GE Healthcare).\nIn 2001, Iodixanol entered the Chinese market.
  • Therefore, the number of equipment still has the potential to increase, which will lead the contrast agent market to expand.

Hyloris Announces Extension of Footprint of Maxigesic® IV into South America

Retrieved on: 
Thursday, May 6, 2021
Drugs, Hepatotoxins, Analgesics, Combination analgesics, Acetanilides, Paracetamol, Pesticides, Ibuprofen, Opioid, Oxycodone/ibuprofen, Hydrocodone/ibuprofen

Maxigesic IV is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion for use post-operatively.

Key Points: 
  • Maxigesic IV is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion for use post-operatively.
  • Moreover, the superior analgesic effect of Maxigesic IV was supported by a range of secondary endpoints, including reduced opioid consumption compared to the paracetamol IV and ibuprofen IV treatment groups (P
  • Hyloris currently has two partnered, commercial-stage products: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic\xc2\xae IV, a non-opioid post-operative pain treatment.
  • The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.\n4 Maxigesic IV Phase 3 study.

Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV

Retrieved on: 
Wednesday, April 28, 2021
Drugs, Hepatotoxins, Analgesics, Combination analgesics, Acetanilides, Paracetamol, Pesticides, Ibuprofen, Opioid, Oxycodone/ibuprofen, Hydrocodone/ibuprofen

Maxigesic IV is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion for use post-operatively.

Key Points: 
  • Maxigesic IV is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion for use post-operatively.
  • Moreover, the superior analgesic effect of Maxigesic IV was supported by a range of secondary endpoints, including reduced opioid consumption compared to the paracetamol IV and ibuprofen IV treatment groups (P
  • Hyloris currently has two partnered, commercial-stage products: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic\xc2\xae IV, a non-opioid post-operative pain treatment.
  • The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.\n4 Maxigesic IV Phase 3 exposure study.

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant

Retrieved on: 
Wednesday, April 14, 2021
Biotechnology, Surgery, Health, Pharmaceutical, Clinical trials, Prosthetics, Medical specialties, Medicine, Surgery, Acetanilides, Bupivacaine, Piperidines, Implant, Collagen

On the day of surgery eligible patients will be randomly assigned to treatment in a 1:1 ratio to receive either XARACOLL or placebo collagen implants.

Key Points: 
  • On the day of surgery eligible patients will be randomly assigned to treatment in a 1:1 ratio to receive either XARACOLL or placebo collagen implants.
  • After a screening period, on the day of surgery, eligible patients will undergo surgery under general anesthesia and have XARACOLL implanted intraoperatively.
  • Innocoll Biotherapeutics plc and its subsidiaries Innocoll Holdings Limited and Innocoll Pharmaceuticals Limited, are focused on the development and commercialization of pharmaceutical technologies to meet some of today\xe2\x80\x99s most important healthcare challenges.
  • XARACOLL implant releases bupivacaine after placement at the surgical site through diffusion from the porous collagen implant, which dissolves over time.